

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
April 17, 2024

Joint presentation about CDK12 at the 76th Annual Meeting of the Japanese Society of Obstetrics and Gynecology

Kanagawa, Japan,
April 17, 2024 – Chordia Therapeutics K.K. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) is pleased to announce that it will co-present on a pre-clinical study of CDK12 inhibitors at the 76th Annual Meeting of the Japanese Society of Obstetrics and Gynecology scheduled for April 19-21, 2024 at Pacifico Yokohama, Japan.

Presentation on CTX-439, CDK12 inhibitor

Title	Advancements in Targeted Therapies Addressing Homologous Recombination Repair Deficiency (HRD) and CDK12 Gene Aberrations in Uterine Serous Carcinoma
-------	---

About Chordia Therapeutics

Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, is developing novel cancer therapies. Chordia's lead asset, CLK inhibitor CTX-712, is currently in Phase 1 clinical study in Japan and Phase 1/2 clinical study in the US. CTX-712 potentially targets vulnerabilities in cancer and could benefit patients with various types of cancer. In addition to CTX-712, Chordia is researching several preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: ir@chorditherapeutics.com